Biblio
Export 1129 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is T [Clear All Filters]
“Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
, “Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.”, J Clin Invest, vol. 122, no. 4, pp. 1316-38, 2012.
, “Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.”, J Clin Invest, vol. 122, no. 4, pp. 1316-38, 2012.
, “An epigenetic blockade of cognitive functions in the neurodegenerating brain.”, Nature, vol. 483, no. 7388, pp. 222-6, 2012.
, “A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.”, Nature, vol. 488, no. 7409, pp. 96-9, 2012.
, “National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.”, Alzheimers Dement, vol. 8, no. 1, pp. 1-13, 2012.
, “National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.”, Alzheimers Dement, vol. 8, no. 1, pp. 1-13, 2012.
, “National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.”, Alzheimers Dement, vol. 8, no. 1, pp. 1-13, 2012.
, “Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults.”, J Alzheimers Dis, vol. 28, no. 1, pp. 93-107, 2012.
, “The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 263-9, 2011.
, “The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 270-9, 2011.
, “Evidence for ordering of Alzheimer disease biomarkers.”, Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
, “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
,